|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fu J and Wang H: Precision diagnosis and
treatment of liver cancer in China. Cancer Lett. 412:283–288. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bosetti C, Turati F and La Vecchia C:
Hepatocellular carcinoma epidemiology. Best Pract Res Clin
Gastroenterol. 28:753–770. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sherman M: Hepatocellular carcinoma:
Epidemiology, surveillance, and diagnosis. Semin Liver Dis.
30:3–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kudo M: Systemic therapy for
hepatocellular carcinoma: 2017 update. Oncology. 93 Suppl
1:S135–S146. 2017. View Article : Google Scholar
|
|
7
|
Costentin CE, Ferrone CR, Arellano RS,
Ganguli S, Hong TS and Zhu AX: Hepatocellular carcinoma with
macrovascular invasion: Defining the optimal treatment strategy.
Liver Cancer. 6:360–374. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kissel M, Berndt S, Fiebig L, Kling S, Ji
Q, Gu Q, Lang T, Hafner FT, Teufel M and Zopf D: Antitumor effects
of regorafenib and sorafenib in preclinical models of
hepatocellular carcinoma. Oncotarget. 8:107096–107108. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sherman M: Regorafenib for treatment of
hepatocellular carcinoma. Hepatology. 67:1162–1165. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bruix J, Qin S, Merle P, Granito A, Huang
YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al:
Regorafenib for patients with hepatocellular carcinoma who
progressed on sorafenib treatment (RESORCE): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Romano G, Veneziano D, Acunzo M and Croce
CM: Small non-coding RNA and cancer. Carcinogenesis. 38:485–491.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang J, Samuels DC, Zhao S, Xiang Y, Zhao
YY and Guo Y: Current research on non-coding ribonucleic acid
(RNA). Genes. 8:pii: E3662017. View Article : Google Scholar
|
|
13
|
Xu G, Yang F, Ding CL, Zhao LJ, Ren H,
Zhao P, Wang W and Qi ZT: Small nucleolar RNA 113-1 suppresses
tumorigenesis in hepatocellular carcinoma. Mol Cancer. 13:2162014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fang X, Yang D, Luo H, Wu S, Dong W, Xiao
J, Yuan S, Ni A, Zhang KJ, Liu XY, et al: SNORD126 promotes HCC and
CRC cell growth by activating the PI3K-AKT pathway through FGFR2. J
Mol Cell Biol. 9:243–255. 2017.PubMed/NCBI
|
|
15
|
Gong J, Li Y, Liu CJ, Xiang Y, Li C, Ye Y,
Zhang Z, Hawke DH, Park PK, Diao L, et al: A Pan-cancer analysis of
the expression and clinical relevance of small nucleolar RNAs in
human cancer. Cell Rep. 21:1968–1981. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu G, Wang LG, Han Y and He QY:
ClusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu J, Lichtenberg T, Hoadley KA, Poisson
LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee
AV, et al: An integrated TCGA Pan-Cancer clinical data resource to
drive High-quality survival outcome analytics. Cell.
173:400–416.e11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jacob H, Stanisavljevic L, Storli KE,
Hestetun KE, Dahl O and Myklebust MP: A four-microRNA classifier as
a novel prognostic marker for tumor recurrence in stage II colon
cancer. Sci Rep. 8:61572018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES, et al: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu L, Chang L, Wang H, Ma W, Peng Q and
Yuan Y: Clinical significance of C/D box small nucleolar RNA U76 as
an oncogene and a prognostic biomarker in hepatocellular carcinoma.
Clin Res Hepatol Gastroenterol. 42:82–91. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ma P, Wang H, Han L, Jing W, Zhou X and
Liu Z: Up-regulation of small nucleolar RNA 78 is correlated with
aggressive phenotype and poor prognosis of hepatocellular
carcinoma. Tumour Biol. Oct 21–2016.(Epub ahead of print).
View Article : Google Scholar
|
|
22
|
Reichow SL, Hamma T, Ferré-D'Amaré AR and
Varani G: The structure and function of small nucleolar
ribonucleoproteins. Nucleic Acids Res. 35:1452–1464. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dong Z, Zhu C, Zhan Q and Jiang W: The
roles of RRP15 in nucleolar formation, ribosome biogenesis and
checkpoint control in human cells. Oncotarget. 8:13240–13252.
2017.PubMed/NCBI
|
|
24
|
Su H, Xu T, Ganapathy S, Shadfan M, Long
M, Huang TH, Thompson I and Yuan ZM: Elevated snoRNA biogenesis is
essential in breast cancer. Oncogene. 33:1348–1358. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Russo A, Saide A, Smaldone S, Faraonio R
and Russo G: Role of uL3 in multidrug resistance in p53-mutated
lung cancer cells. Int J Mol Sci. 18:pii: E5472017. View Article : Google Scholar
|
|
26
|
Yuan F, Zhang Y, Ma L, Cheng Q, Li G and
Tong T: Enhanced NOLC1 promotes cell senescence and represses
hepatocellular carcinoma cell proliferation by disturbing the
organization of nucleolus. Aging Cell. 16:726–737. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cristescu R, Lee J, Nebozhyn M, Kim KM,
Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular
analysis of gastric cancer identifies subtypes associated with
distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Z, Wu Q, Feng S, Zhao Y and Tao C:
Identification of four prognostic LncRNAs for survival prediction
of patients with hepatocellular carcinoma. PeerJ. 5:e35752017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu G, Wang H, Fu JD, Liu JY, Yan AG and
Guan YY: A five-miRNA expression signature predicts survival in
hepatocellular carcinoma. APMIS. 125:614–622. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li B, Feng W, Luo O, Xu T, Cao Y, Wu H, Yu
D and Ding Y: Development and validation of a three-gene prognostic
signature for patients with hepatocellular carcinoma. Sci Rep.
7:55172017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mannoor K, Liao J and Jiang F: Small
nucleolar RNAs in cancer. Biochim Biophys Acta. 1826:121–128.
2012.PubMed/NCBI
|
|
32
|
Warner WA, Spencer DH, Trissal M, White
BS, Helton N, Ley TJ and Link DC: Expression profiling of snoRNAs
in normal hematopoiesis and AML. Blood Adv. 2:151–163. 2018.
View Article : Google Scholar : PubMed/NCBI
|
